Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 17, 2008 - Issue 10
Submit an article Journal homepage
208
Views
8
CrossRef citations to date
0
Altmetric
Review

Investigational drugs for diabetic nephropathy

Monica Cortinovis Mario Negri Institute for Pharmacological Research, Department of Medicine and Transplantation, Ospedali Riuniti di Bergamo, Via Gavazzeni 11, 24125 Bergamo, Italy +39 035 319888; +39 035 319331; [email protected]
,
Dario Cattaneo Mario Negri Institute for Pharmacological Research, Department of Medicine and Transplantation, Ospedali Riuniti di Bergamo, Via Gavazzeni 11, 24125 Bergamo, Italy +39 035 319888; +39 035 319331; [email protected]
,
Norberto Perico Mario Negri Institute for Pharmacological Research, Department of Medicine and Transplantation, Ospedali Riuniti di Bergamo, Via Gavazzeni 11, 24125 Bergamo, Italy +39 035 319888; +39 035 319331; [email protected]
&
Giuseppe Remuzzi Mario Negri Institute for Pharmacological Research, Department of Medicine and Transplantation, Ospedali Riuniti di Bergamo, Via Gavazzeni 11, 24125 Bergamo, Italy +39 035 319888; +39 035 319331; [email protected]
Pages 1487-1500 | Published online: 22 Sep 2008

Bibliography

  • The World Health Organization 2007. Diabetes Programme: facts and figures. Available from: http://www.who.int/diabetes/facts/en [Last accessed 25 February 2007]
  • Parving HH, Hovind P, Rossing K, Andersen S. Evolving strategies for renoprotection: diabetic nephropathy. Curr Opin Nephrol Hypertens 2001;10:515-22
  • Villar E, Remontet L, Labeeuw M, et al. Effects of age, gender and diabetes on excess death in end-stage renal failure. J Am Soc Nephrol 2007;18:2125-34
  • Ruggenenti P, Remuzzi G. Time to abandon microalbuminuria? Kidney Int 2006;70:1214-22
  • Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108:2154-69
  • Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 1997;157:1413-8
  • Bruno S, Cattaneo D, Perico N, Remuzzi G. Emerging drugs for diabetic nephropathy. Expert Opin Emerging Drugs 2005;10:747-71
  • Gaspari F, Perico N, Remuzzi G. Measurement of glomerular filtration rate. Kidney Int 1997;63:S151-4
  • Fontseré N, Salinas I, Bonal J, et al. Are prediction equations for glomerular filtration rate useful for the long-term monitoring of type 2 diabetic patients? Nephrol Dial Transplant 2006;21:2152-8
  • Bakris GL. Slowing nephropathy progression: focus on proteinuria reduction. Clin J Am Soc Nephrol 2008;3:S3-10
  • Jermendy G, Ruggenenti P. Preventing microalbuminuria in patients with type 2 diabetes. Diabetes Metab Res Rev 2007;23:100-10
  • Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000;32:412-9
  • Miyata K, Rahman M, Shokoji T, et al. Aldosterone stimulates reactive oxygen species production through activation of NADPH oxidase in rat mesangial cells. J Am Soc Nephrol 2005;16:2906-12
  • Remuzzi G, Macia M, Ruggenenti P. Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study. J Am Soc Nephrol 2006;17(4 Suppl 2):S90-7
  • Keane WF, Zhang Z, Lyle PA, et al. Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study. Clin J Am Soc Nephrol 2006;1:761-7
  • Ruggenenti P, Perna A, Loriga G, et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet 2005;365:939-46
  • Remuzzi G, Perico N, Macia M, Ruggenenti P. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int Suppl 2005;99:S57-65
  • Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60
  • Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9
  • Viberti G, Viberti G, Wheeldon NM, et al. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002;106:672-8
  • Parving HH, Lehnert H, Bröchner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8
  • Makino H, Haneda M, Babazono T, et al. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 2007;30:1577-8
  • Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004;351:1941-51
  • Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370:829-40
  • Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000;321:1440-4
  • Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003;361:117-24
  • Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59
  • Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456-62
  • Barnett A. Prevention of loss of renal function over time in patients with diabetic nephropathy. Am J Med 2006;119:S40-7
  • Wolf G. Renal injury due to renin-angiotensin-aldosterone system activation of the transforming growth factor-β pathway. Kidney Int 2006;70:1914-19
  • Huang W, Xu C, Kahng KW, et al. Aldosterone and TGF-beta 1 synergistically increase PAI-1 and decrease matrix degradation in rat renal mesangial and fibroblast cells. Am J Physiol Renal Physiol 2008;294:F1187-F95
  • Delyani JA. Mineralcorticoid receptor antagonists: the evolution of utility and pharmacology. Kidney Int 2000;57:1409-11
  • Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 2007;3:486-92
  • Sato A, Satura T. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res 2001;29:13-21
  • Sato A, Hayashi K, Saruta T. Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens 2005;18:44-9
  • Epstein M, Williams GH, Weinberger M, Lewin A. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006;1:940-51
  • Schjoedt KJ, Schjoedt KJ, Rossing K, et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int 2005;68:2829-36
  • Van den Meiracher AH, Baggen RG, Pauli S, et al. Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function. J Hypertens 2006;24:2285-92
  • Bianchi S, Bigazzi R, Campese VM. Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study. Am J Kidney Dis 2005;46:45-51
  • Cravedi P, Ruggenenti P, Remuzzi G. Intensified inhibition of renin-angiotensin system: a way to improve renal protection? Curr Hypertens Rep 2007;9:430-6
  • Hui KY, Carlson WD, Bernatowicz MS, Haber E. Analysis of structure-activity relationships in renin substrate analogue inhibitory peptides. J Med Chem 1987;30:1287-95
  • Boger J, Payne LS, Perlow DS, et al. Renin inhibitors. Syntheses of subnanomolar, competitive, transition-state inhibitors containing a novel analogue of statine. J Med Chem 1985;28:1779-90
  • Van Paassen P, de Zeeuw D, Navis G, de Jong PE. Renal and systemic effects of continued treatment with renin inhibitor remikiren in hypertensive patients with normal and impaired renal function. Nephrol Dial Transplant 2000;15:637-43
  • Parving HH, Persson F, Lewis JB, et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008;358:2433-46
  • Speedel website.Available from: http://www.speedel.com
  • Weber MA. Vasopeptidase inhibitors. Lancet 2001;358:1525-32
  • Kakoki M, Takahashi N, Jennette JC, et al. Diabetic nephropathy is markedly enhanced in mice lacking the bradykinin B2 receptor. Proc Natl Acad Sci USA 2004;101:13302-5
  • Fredersdorf S, Weil J, Ulucan C, et al. Vasopeptidase inhibition attenuates proteinuria and podocyte injury in Zucker diabetic fatty rats. Naunyn Schmiedebergs Arch Pharmacol 2007;375:95-103
  • Kostis JB, Packer M, Black HR, et al. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens 2004;17:103-11
  • Tabrizchi R. Ilepatril (AVE-7688), a vasopeptidase inhibitor for the treatment of hypertension. Curr Opin Investig Drugs 2008;9:301-9
  • Hayashino Y, Fukuhara S, Akiba T, et al. Diabetes, glycaemic control and mortality risk in patients on haemodialysis: the Japan Dialysis Outcomes and Practice Pattern Study. Diabetologia 2007;50:1170-7
  • Nathan DM. Clinical practice. Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med 2002;347:1342-9
  • Graham DJ, Green L, Senior JR, Nourjah P. Troglitazone-induce liver failure: a case study. Am J Med 2003;114:299-306
  • Miyazaki Y, Cersosimo E, Triplitt C, DeFronzo RA. Rosiglitazone decreases albuminuria in type 2 diabetic patients. Kidney Int 2007;72:1367-73
  • Kamijo A, Kimura K, Sugaya T, et al. Urinary free fatty acids bound to albumin aggravate tubulointerstitial damage. Kidney Int 2002;62:1628-37
  • Bakris GL, Ruilope LM, McMorm SO, et al. Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. J Hypertens 2006;25:2047-55
  • Lebovitz HE, Dole JF, Patwardhan R, et al. Rosiglitazone monotherapy is effective in type 2 diabetes. J Clin Endocrinol Metab 2001;86:280-8
  • Pistrosch F, Herbrig K, Kindel B, et al. Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria in incipient diabetic nephropathy in patients. Diabetes 2005;54:2206-11
  • Nakamura T, Sugaya T, Kawagoe Y, et al. Effect of Pioglitazone on urinary liver-type fatty acid-binding protein concentrations in diabetes patients with microalbuminuria. Diabetes Metab Res Rev 2006;22:385-9
  • Guan Y, Hao C, Cha DR, et al. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 2005;11:861-6
  • Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71
  • Cattaneo D, Remuzzi G. Lipid oxidative stress and the anti-inflammatory properties of statins and ACE inhibitors. J Ren Nutr 2005;15:71-6
  • Douglas K, O'Malley PG, Jackson JL. Meta-analysis: the effect of statins on albuminuria. Ann Intern Med 2006;145:117-24
  • UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998;352:837-53
  • The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86
  • Schrier RW, Estacio RO, Esler A, et al. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002;61:1086-97
  • Yan SF, Ramasamy R, Bucciarelli LG, et al. RAGE and its ligands: a lasting memory in diabetic complications? Diab Vasc Dis Res 2004;1:10-20
  • Wautier MP, Chappey O, Corda S, et al. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 2001;280:E685-94
  • Wendt T, Tanji N, Guo J, et al. Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy. J Am Soc Nephrol 2003;14:1383-95
  • Corbett JA, Tilton RG, Chang K, et al. Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes 1992;41:552-6
  • Bolton WK, Cattran DC, Williams ME, et al. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol 2004;24:32-40
  • The Pharmaprojects Database, Informa UK Ltd 2008. Available from: www.pharmaprojects.com [Last accessed 10 June 2008]
  • Remuzzi G, Benigni A. Endothelins in the control of cardiovascular and renal function. Lancet 1993;342:589-93
  • Benigni A, Perico N, Remuzzi G. Research on renal endothelin in proteinuric nephropathies dictates novel strategies to prevent progression. Curr Opin Nephrol Hypertens 2001;10:1-6
  • Ruiz-Ortega M, Gomez-Garre D, Alcazar R, et al. Involvement of angiotensin II and endothelin in matrix protein production and renal sclerosis. J Hypertens Suppl 1994;12:S51-8
  • Hargrove GM, Dufresne J, Whiteside C, et al. Diabetes mellitus increases endothelin-1 gene transcription in rat kidney. Kidney Int 2000;58:1534-45
  • Tuttle KR, McGill JB, Haney DJ, et al. PKC-DRS, PKC-DMES, and PKC-DRS 2 Study Groups Kidney outcomes in long-term studies of ruboxistaurin for diabetic eye disease. Clin J Am Soc Nephrol 2007;2:631-6
  • Tuttle KR, Bakris GL, Toto RD, et al. The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 2005;28:2686-90
  • Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes 1998;47:859-66
  • Derubertis FR, Craven PA. Activation of protein kinase C in glomerulare cells in diabetes. Mechanisms and potential links to the pathogenesis of diabetic nephropathy. Diabetes 1994;43:1-8
  • The PKC-DRS2 Study Group. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology 2006;113:2221-30
  • Van der Jagt DL, Robinson B, Taylor KK, Hunsaker LA. Aldose reductase from human skeletal and heart muscle: interconvertible forms related by thiol-disulfide exchange. J Biol Chem 1990;265:20982-7
  • Kasajima H, Yamagishi S, Sugai S, et al. Enhanced in situ expression of aldose reductase in peripheral nerve and renal glomeruli in diabetic patients. Virchows Arch 2001;439:46-54
  • Shah VO, Dorin RI, Sun Y, et al. Aldose reductase gene expression is increased in diabetic nephropathy. J Clin Endocrinol Metab 1997;82:2294-98
  • Demaine AG. Polymorphisms in the aldose reductase gene and susceptibility to diabetic microvascular complications. Curr Med Chem 2003;10:1389
  • Xu M, Chen X, Yan L, et al. Association between (AC)n dinucleotide repeat polymorphism at the 5′-end of the aldose reductase gene and diabetic nephropathy: a meta-analysis. J Mol Endocrinol 2008;40:243-51
  • Oates PJ, Mylari BL. Aldose reductase inhibitors: therapeutic implications for diabetic complications. Expert Opin Investig Drugs 1999;8:2095-119
  • Pedersen MM, Christiansen JS, Mogensen CE. Reduction of glomerular hyperfiltration in normoalbuminuric IDDM patients by 6 mo of aldose reductase inhibition. Diabetes 1991;40:527-31
  • Passariello N, Sepe J, Marrazzo G, et al. Effect of aldose reductase inhibitor (tolrestat) on urinary albumin excretion rate and glomerular filtration rate in IDDM subjects with nephropathy. Diabetes Care 1993;16:789-95
  • Iso K, Tada H, Kuboki K, Inokuchi T. Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in Type 2 diabetic patients. J Diabetes Complications 2001;15:241-4
  • Xu X, Rao G, Maxhimer JB, et al. Mechanism of action of sulodexide-mediated control of diabetic proteinuria: inhibition of heparanase-1 activity [abstract]. J Am Soc Nephrol 2005;16:637
  • Gambaro G, Kinalska I, Oksa A, et al. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the DiNAS randomized trial. J Am Soc Nephrol 2002;13:1615-25
  • Heerspink HL, Greene T, Lewis JB, et al. Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria. Nephrol Dial Transplant 2008;23:1946-54
  • Keryx Biopharmaceuticals. The Collaborative Study Group. Effect of sulodexide in early diabetic nephropathy. ClinicalTrials.gov, NIH. Available from: http://clinicaltrials.gov/ct/show/NCT00130312?ORDER= [Last accessed 6 November 2007]
  • Keryx Biopharmaceuticals. The Collaborative Study Group. Effect of sulodexide in overt type 2 diabetic nephropathy. ClinicalTrials.gov, NIH. Available from: http://clinicaltrials.gov/ct/show/NCT00130312?ORDER= [Last accessed 12 June 2007]
  • Available from: http://www.keryx.com
  • Yamamoto T, Nakamura T, Noble NA, et al. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 1993;90:1814-8
  • Sharma K, Ziyadeh FN. The emerging role of transforming growth factor-beta in kidney diseases. Am J Physiol 1994;266:F829-42
  • Di Paolo S, Gesualdo L, Ranieri E, et al. High glucose concentration induces the overexpression of transforming growth factor-β through the activation of a platelet-derived growth factor loop in human mesangial cells. Am J Pathol 1996;149:2095-106
  • Navarro JF, Mora C, Muros M, Garcia J. Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial. J Am Soc Nephrol 2005;16:2119-26
  • McCormick BB, Sydor A, Akbari A, et al. The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis. Am J Kidney Dis 2008;52(3):454-63
  • Rodríguez-Morán M, Guerrero-Romero F. Pentoxifylline is as effective as captopril in the reduction of microalbuminuria in non-hypertensive type 2 diabetic patients: a randomized, equivalent trial. Clin Nephrol 2005;64:91-7
  • Aminorroaya A, Janghorbani M, Rezvanian H, et al. Comparison of the effect of pentoxifylline and captopril on proteinuria in patients with type 2 diabetes mellitus. Nephron Clin Pract 2005;99:73-7
  • Jacobsen P, Andersen S, Rossing K, et al. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int 2003;63:1874-80
  • Pisoni R, Ruggenenti P, Sangalli F, et al. Effect of high-dose ramipril with or without indomethacin on glomerular selectivity. Kidney Int 2002;62:1010-9
  • Shafiq MM, Menon DV, Victor RG. Oral direct renin inhibition: premise, promise, and potential limitations of a new antihypertensive drug. Am J Med 2008;121:265-71
  • Nussberger J, Gradman AH, Schmieder RE, et al. Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. Int J Clin Pract 2007;61:1461-8
  • Trask AJ, Ferrario CM. Angiotensin-(1-7): pharmacology and new perspectives in cardiovascular treatments. Cardiovasc Drug Rev 2007;25:162-74
  • Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-93
  • Ruggenenti P, Perticucci E, Cravedi P, et al. Role of remission clinics in the longitudinal treatment of CKD. J Am Soc Nephrol 2008;19:1213-24
  • Orth SR, Stöckmann A, Conradt C, et al. Smoking as a risk factor for end-stage renal failure in men with primary renal disease. Kidney Int 1998;54:926-31
  • Orth SR, Hallan SI. Smoking: a risk factor for progression of chronic kidney disease and for cardiovascular morbidity and mortality in renal patients: absence of evidence or evidence of absence? Clin J Am Soc Nephrol 2008;3:226-36
  • Thijssen S, Kitzler TM, Levin NW. Salt: its role in chronic kidney disease. J Ren Nutr 2008;18:18-26
  • Foreyt JP, Poston WS II. The challenge of diet, exercise and lifestyle modification in the management of the obese diabetic patient. Int J Obes Relat Metab Disord 1999;23(Suppl 7):S5-11

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.